VVOS News and Press, Vivos Therapeutics Inc. From 07/01/21

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA&#x...

Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial Epigenetics The book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovation The ...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), was featured in a recent episod...

Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overal...

HIGHLANDS RANCH, Colo., May 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients sufferi...

Vivos Therapeutics, Inc. (VVOS) Q1 2021 Earnings Conference Call May 17, 2021 5:00 PM ET Company Participants Edward Loew - IR Kirk Huntsman - CEO Brad Amman - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Scott Henry - ROTH Capital Presentation Operator Good afternoon, a...

Vivos Therapeutics (VVOS): Q1 GAAP EPS of -$0.19 misses by $0.02.Revenue of $3.45M (+7.8% Y/Y) beats by $0.2M.Gross margin increased to 78% for the first quarter of 2021, compared to 76% for the first quarter of 2020.Cash and cash equivalents were $14.1 million at March 31, 2021, and cash was...

HIGHLANDS RANCH, Colo., May 17, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suf...

HIGHLANDS RANCH, Colo., May 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disord...

HIGHLANDS RANCH, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-mo...